Evidence map›Paper›PMID 30724789›Full record

ReviewCurrent opinion in infectious diseases2019

Influenza virus polymerase inhibitors in clinical development.

Frederick G Hayden, Nahoko Shindo

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current opinion in infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 115 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
115citing papers in PubMed, 3 pooled it
28.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

115 citing papers in PubMed, 3 syntheses or guidelines pooled it, 253 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Article
  10. Review
  11. DNA Nanostructure-Templated Multivalency Enables Broad-Spectrum Virus Inhibition.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

55 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Frederick G HaydenDepartment of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
Nahoko ShindoHealth Emergencies Programme, World Health Organization, Geneva, Switzerland.
University of Virginia · USWorld Health Organization · CH

Funding

World Health Organization 001
6 · The paper itself

Abstract

purpose of reviewWe review antivirals inhibiting subunits of the influenza polymerase complex that are advancing in clinical development. RECENT

findingsFavipiravir, pimodivir, and baloxavir are inhibitory in preclinical models for influenza A viruses, including pandemic threat viruses and those resistant to currently approved antivirals, and two (favipiravir and baloxavir) also inhibit influenza B viruses. All are orally administered, although the dosing regimens vary. The polymerase basic protein 1 transcriptase inhibitor favipiravir has shown inconsistent clinical effects in uncomplicated influenza, and is teratogenic effects in multiple species, contraindicating its use in pregnancy. The polymerase basic protein 2 cap-binding inhibitor pimodivir displays antiviral effects alone and in combination with oseltamivir in uncomplicated influenza, although variants with reduced susceptibility emerge frequently during monotherapy. Single doses of the polymerase acidic protein cap-dependent endonuclease inhibitor baloxavir are effective in alleviating symptoms and rapidly inhibiting viral replication in otherwise healthy and higher risk patients with acute influenza, although variants with reduced susceptibility emerge frequently during monotherapy. Combinations of newer polymerase inhibitors with neuraminidase inhibitors show synergy in preclinical models and are currently undergoing clinical testing in hospitalized patients. SUMMARY: These new polymerase inhibitors promise to add to the clinical management options and overall control strategies for influenza virus infections.

Indexed as

Antiviral AgentsClinical Trials as TopicDrug DevelopmentEndoribonucleasesHumansInfluenza, HumanOrthomyxoviridaeRNA-Dependent RNA PolymeraseViral ProteinsAntiviral AgentsEndoribonucleasesinfluenza virus polymerase basic protein 1methylated cap-dependent endonucleasePB2 protein, Influenzavirus ARNA-Dependent RNA PolymeraseViral Proteins

Identifiers

PMID30724789
PMCPMC6416007
OpenAlexW2911505242

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.